Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 3/20 | 0.38 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 8/20 | 0.34 |
| ▸ | BCHE | P06276 | 4/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277460 | 0.84 | NOS3 (0.39) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL19995820 | 0.79 | NOS3 (0.36) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL13091632 | 0.75 | CYP3A4 (0.34) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL12057393 | 0.74 | MEN1 (0.61) | MEN1KMT2AALDH1A1CES1KDM4E | |
| SCHEMBL14204852 | 0.74 | MEN1 (0.43) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL23808911 | 0.74 | ACHE (0.44) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL19791796 | 0.72 | ACHE (0.46) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL20002035 | 0.71 | ALDH1A1 (0.39) | NOS3NOS1NOS2ALDH1A1TP53 | |
| SCHEMBL19266204 | 0.71 | NOS3 (0.44) | MEN1KMT2ANOS3NOS1NOS2 | |
| SCHEMBL13091633 | 0.71 | KDM4E (0.40) | MEN1KMT2AALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134226-B1 | Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex | TAKASAGO PERFUMERY CO LTD (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-6596887-B2 | Reacting a ruthenium-phosphine complex with a specific optically active chiral diamine to deactivate one of the enantiomers and with another diamine to activate the other enantiomers | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20010039354-A1 | Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2001-11-08 | — | — | US | disclosed |
| EP-1134226-A2 | Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex | Takasago International Corporation (JP) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039354-A1 | Process for producing an optically active ruthenium-phosphine complex and process for producing an optically active alcohol by using the complex | DRD4, PNMT, DRD1 | MEN1 2356/4885KMT2A 2853/4885NOS3 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.